Solara Active Pharma Sciences Limited announced its financial results for the quarter ended December 31, 2024, showing a consistent performance across key financial metrics.
Key Financial Highlights:
- Revenue from Operations: ₹300.31 crore, a significant 41.6% YoY increase compared to ₹211.94 crore in Q3 FY24. Sequentially, it declined 13.5% QoQ from ₹346.95 crore.
- Total Income: ₹301.80 crore, up 42.1% YoY from ₹212.39 crore in Q3 FY24. QoQ, it fell 13% from ₹347.27 crore.
- Net Profit: ₹8.09 crore, compared to a loss of ₹275.34 crore in Q3 FY24. Sequentially, it remained flat at ₹8.01 crore in Q2 FY25.
Nine-Month Performance:
- Revenue from Operations: ₹1,010.75 crore, a 2.2% YoY increase from ₹989.49 crore.
- Net Profit: ₹2.64 crore, against a loss of ₹321.76 crore during the same period in the previous year.
Operational Highlights:
- The company attributed the improved performance to cost management strategies and better operational efficiency.
- Total Expenses: ₹293.74 crore in Q3 FY25, down from ₹339.26 crore in Q2 FY25, driven by a reduction in material and employee expenses.
We are pleased with our Q3 performance. While our Revenues are muted for the quarter, our relentless focus on profitable growth resulted in Gross margins of 55.4% reaching the historical levels. This initiative includes letting go off certain non-profitable businesses which were bringing down our margin profile. : As an outcome of course correction measures, the Company is pleased | to report an improved EBITDA margin of 19.6% inching closer towards E the Q4 exit quarter guidance. Our ongoing actions on improving : profitability through cost improvement programs, operating cost : optimization, enhancing R&D productivity, optimizing working capital i and debt will continue to yield benefits. Our Regulated market revenues continue to be at 76% of total revenues. We are confident in continuing the growth momentum and are on track to continuously improve the quality of our earnings while strengthening our balance sheet – Poorvank Purohit, CEO
Disclaimer: The information provided is for informational purposes only and should not be considered as financial or investment advice. Always conduct your research or consult a financial advisor before making investment decisions.
